   |
|
Prior to joining Selecta Biosciences, Dr. Cautreels was CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories in February 2010. Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was their Global Head of R&D. Prior to joining Solvay, he was employed by Sanofi, Sterling-Winthrop, and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA) from 1999-2006. He is currently a director of Selecta and Galapagos NV (Mechelen, Belgium). He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He was born in Antwerp, Belgium, and graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
Dr. Cole is a General Partner at Flagship Ventures where he focuses on Life Science investments. Prior to Flagship, he served as Program Executive at Vertex Pharmaceuticals, Medical Director at Cytotherapeutics, and as Instructor in Neurology at Harvard Medical School. While at Flagship, he has led investments in Agios Pharmaceuticals, Tetraphase, Quanterix, Concert Pharmaceuticals, Ensemble Discovery, Alvine Pharmaceuticals, Seventh Sense, and CombinatoRx. Dr. Cole co-founded Ensemble Discovery and served as CEO of the company during its initial stages. He currently represents Flagship on the Board of Directors at Agios Pharmaceuticals, Tetraphase, Concert Pharmaceuticals, Ensemble Discovery, AVEO Pharmaceuticals, Quanterix, and CGI Pharmaceuticals, and is an Observer on the Board of Directors of Alvine. Dr. Cole obtained post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at Massachusetts General Hospital. He holds an M.D. from the University of Pennsylvania School of Medicine and received an A.B. magna cum laude with High Distinction in English from Dartmouth College.
Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is additionally a member of the DanaFarber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He is a Research Affiliate in the MIT Institute for Medical Engineering and Science. Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput development and screening of multi functional nanoparticles for medical applications. Dr. Farokhzad has authored more than 85papers and is an inventor of more than 70 issued/pending patents. The nanoparticle technologies that Dr. Farokhzad has developed formed the foundation for the launch of three venture-backed biotechnology companies, BIND Therapeutics, Selecta Biosciences and Blend Therapeutics. These companies are translating the aforementioned academic innovations towards clinical development. He serves as Director on the boards of BIND and Blend, and as Director and Vice Chairman on the board of Selecta. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.
Dr. Gordon is Co-Head of Private Equity and founding General Partner of OrbiMed Advisors, where he is active in both private equity and small-capitalization public equity investments. Before OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, and is a Certified Financial Analyst. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology with his dissertation focusing on protein folding and assembly. He completed a fellowship at The Rockefeller University and earned a Bachelor's degree from Harvard College.
Mr. Hutt is a senior counsel in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law. Mr. Hutt served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country. Mr. Hutt has been a member of the Institute of Medicine since it was founded in 1971, and he currently serves on the Panel on the Administrative Restructuring of the National Institutes of Health. He also serves on academic and venture capital advisory boards, and the boards of numerous startup biotechnology companies. He was named by The Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C.
Dr. Langer is one of 14 Institute Professors at MIT and has done pioneering work in the use of biomaterials for tissue engineering and drug delivery, most recently applying nanotechnology for developing novel targeted strategies for cancer therapy. Professor Langer has written over 1,150 articles. He also has approximately 800 issued/pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology, and medical device companies. He is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and AIR. Professor Langer is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. In July 2007, he was awarded the National Medal of Science, the highest civilian honor bestowed by the United States. Dr. Langer received his B.S. from Cornell University and his Sc.D. from the Massachusetts Institute of Technology, both in Chemical Engineering.
Dr. Nashat is a General Partner at Polaris Venture Partners and focuses on investments in the life sciences. Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at MIT with a minor in Biology under the guidance of Dr. Robert Langer. During his time at MIT, Amir completed an internship in the London office of Goldman, Sachs & Company, where he worked on interest rate derivative products. Amir currently represents Polaris as a Director of Adnexus Therapeutics, Athenix Corporation, aTyr Pharmaceutials, Avila Therapeutics, Hydra Biosciences, Promedior Pharmaceuticals, Pervasis Therapeutics, where he was founding president, T2 Biosystems, and WaveRx. He also serves on the Board of the New England Venture Capital Association, on the Advisory Board of the Simmons School of Management Entrepreneurship Initiative, and is a Catalyst for the Deshpande Center for Technological Innovation at MIT. He received his Ph.D. at MIT, and both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Aymeric Sallin is the Founder and Managing Director of NanoDimension. Aymeric has led investments in Crocus Technology, Xtellus, and Selecta Biosciences and currently represents NanoDimension on the Board of Crocus Technology and Selecta Biosciences. Aymeric has received the "NSTI Fellow Award" for outstanding contributions to the advancement of the international nanotechnology community. Prior to NanoDimension, Aymeric was a strategy consultant at Bain & Company focusing on the high-tech industry. Aymeric received a Masters Degree in Physical Engineering from the Federal Institute of Technology (EPFL) in Lausanne, Switzerland and currently serves on the Advisory Board of the Physics Department.
Dr. Siber is widely regarded as one of the leading global authorities in vaccines and was previously the Executive Vice President and Chief Scientific Officer of Wyeth Vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). Prior to joining Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber oversaw research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against RSV, which was the precursor of Synagis.
Prior to joining RUSNANO Yurii Udaltsov was the Head of Reform Management Center of RAO UES of Russia. Former "chief reformer" of electricity system in Russia now represents RUSNANO in innovation policy and expert support of innovation development of Russian Federation. Also he is a Member of the Board of Directors of Russian Venture Company and Member of the Grand committee of Skolkovo Foundation.